Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Michael

Showing results (951-960 of 1,306) with videos related to

Pageof 131
Sort By:
JACC. Heart Failure|December 21, 2023
Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection FractionMichael A Fuery, Eric S Leifer, Marc D Samsky, et al.
Canadian Family Physician Medecin De Famille Canadien|October 17, 2015
Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary careG Michael Allan, Adrienne J Lindblad, Ann Comeau, et al.
Circulation|May 25, 2005
Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotypeLi Zhang, D Woodrow Benson, Martin Tristani-Firouzi, et al.
Circulation. Cardiovascular Genetics|August 12, 2011
Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutationAlon Barsheshet, Arthur J Moss, Scott McNitt, et al.
European Journal of Heart Failure|November 22, 2023
Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS-986231)Pierpaolo Pellicori, John G F Cleland, Maria Borentain, et al.
European Journal of Heart Failure|March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trialAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
Nature Medicine|March 30, 2026
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trialScott D Solomon, John J V McMurray, G Michael Felker, et al.
Journal of the American Heart Association|May 9, 2023
Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection FractionJosephine Harrington, Jie-Lena Sun, Gregg C Fonarow, et al.
European Journal of Heart Failure|September 17, 2022
Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fractionBart J van Essen, Jasper Tromp, Jozine M Ter Maaten, et al.
Journal of the American Heart Association|January 16, 2020
Provider Perspectives on the Feasibility and Utility of Routine Patient-Reported Outcomes Assessment in Heart Failure: A Qualitative AnalysisPeter Wohlfahrt, Susan L Zickmund, Stacey Slager, et al.
Pageof 131

Showing results (951-960 of 1,306) with videos related to

Sort By:
Pageof 131
JACC. Heart Failure|December 21, 2023
Prognostic Impact of Repeated NT-proBNP Measurements in Patients With Heart Failure With Reduced Ejection FractionMichael A Fuery, Eric S Leifer, Marc D Samsky, et al.
Canadian Family Physician Medecin De Famille Canadien|October 17, 2015
Simplified lipid guidelines: Prevention and management of cardiovascular disease in primary careG Michael Allan, Adrienne J Lindblad, Ann Comeau, et al.
Circulation|May 25, 2005
Electrocardiographic features in Andersen-Tawil syndrome patients with KCNJ2 mutations: characteristic T-U-wave patterns predict the KCNJ2 genotypeLi Zhang, D Woodrow Benson, Martin Tristani-Firouzi, et al.
Circulation. Cardiovascular Genetics|August 12, 2011
Risk of syncope in family members who are genotype-negative for a family-associated long-QT syndrome mutationAlon Barsheshet, Arthur J Moss, Scott McNitt, et al.
European Journal of Heart Failure|November 22, 2023
Impact of vasodilators on diuretic response in patients with congestive heart failure: A mechanistic trial of cimlanod (BMS-986231)Pierpaolo Pellicori, John G F Cleland, Maria Borentain, et al.
European Journal of Heart Failure|March 2, 2026
Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trialAlberto Foà, Muthiah Vaduganathan, Brian L Claggett, et al.
Nature Medicine|March 30, 2026
The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trialScott D Solomon, John J V McMurray, G Michael Felker, et al.
Journal of the American Heart Association|May 9, 2023
Clinical Profile, Health Care Costs, and Outcomes of Patients Hospitalized for Heart Failure With Severely Reduced Ejection FractionJosephine Harrington, Jie-Lena Sun, Gregg C Fonarow, et al.
European Journal of Heart Failure|September 17, 2022
Characteristics and clinical outcomes of patients with acute heart failure with a supranormal left ventricular ejection fractionBart J van Essen, Jasper Tromp, Jozine M Ter Maaten, et al.
Journal of the American Heart Association|January 16, 2020
Provider Perspectives on the Feasibility and Utility of Routine Patient-Reported Outcomes Assessment in Heart Failure: A Qualitative AnalysisPeter Wohlfahrt, Susan L Zickmund, Stacey Slager, et al.
Pageof 131